The Maintrac Tumour Sphere Units Test
Some CTCs may have stem-cell qualities. These CTCs may have the ability to hide from treatment and form a second tumour, called a metastasis. This test determines whether a person’s CTCs can multiply to form microscopic clusters, called Tumour Sphere Units, in the laboratory. CTCs that can form clusters have stem cell qualities, rendering them more resistant to treatment and capable of initiating metastatic spread of cancer.
Assessing the risk of cancer spread is now possible. The Maintrac® Tumour Sphere Units test can be used to:
- Determine the level of aggressiveness of a person’s cancer
- Assess the potential for cancer spread
- Detect the risk of metastasis, a second tumour, early
The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC count test every 3-6 months.
Maintrac® is a state-of-the-art German technology that detects, characterises and tests CTCs. It has been critically validated and published in peer reviewed journals for over 12 years. Maintrac® CTC tests are acknowledged and utilised by many universities, Oncologists and cancer clinics worldwide.
This test can only be ordered in addition to a CTC Count, which is $720 in Australia and $820 in New Zealand.
Tumour Sphere Units test: $1,900
Please note a period of 21 days growth in media is required for this test.
Prices are in AUD and subject to change without notice
ORDER A TEST
Complete instructions for ordering a test, blood sample collection and dispatch can be found here
Tests can only be ordered by registered, certificed Healthcare Practitioners.
To order a test, download the request form and take it with you to the next appointment with your treating healthcare practitioner.